Audit of Neoadjuvant Chemotherapy in management of breast cancer – our unit experience
Association of Breast Surgery ePoster Library. Rashid S. 05/13/19; 257142; P098
Sabina Rashid
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P098
Topic: Non surgical treatments
Introduction: Neoadjuvant Chemotherapy(NAC) is offered to ER negative, HER2 positive women where tumour size may be reduced. Concerns regarding increased local recurrence rates and length of disease-free survival may influence MDT decision making. Methods This audit reports a single unit experience, over 2 years, in 62 patients who underwent NAC and their radiological and pathological response to treatment. Results: The mean age of this cohort was 46.5 years.Out of 42 symptomatic(67.7%) patients 28(45%) presented within 4 weeks. Eight(12.9%) were screen detected.Commonest TNM presentation was T2(33)N1(35)M0(59). Indication for NAC was breast conservation in the majority(54,62%), followed by ER-ve,Her2 +vity(10,16.1%), locally advanced tumour(15,24.1%), inflammatory(8,12.9%) and triple negative tumours in <50 years(11,17.7%). 32 (52%) women had ER positive,13 (21%) had HER2 positive and 20(32%) had triple negative cancers.Excellent radiological(MRI) response was seen in 17(27.4%) and partial response in 38(61.2%) patients.44 (71%) underwent breast conserving surgery(BCS) while 18(29%) had mastectomy. Fifteen(24.19%) had their decision for mastectomy changed after NAC.Eleven(18%) had a complete pathological response(CpR). All patients had undergone surgery within 8 weeks of final NAC. Four(6.4%)patients were reported to have local recurrence(LR) at the conclusion of the audit period.ConclusionPatients offered NAC in our unit fit the criteria suggested by NICE guidelines. Our rates of CpR(18%Vs.15-36.6%), improved BCS rates post NAC(24.9%Vs.16-25%) and LR rates(6.4%Vs.6%) are acceptable and comparable to the literature.
Topic: Non surgical treatments
Introduction: Neoadjuvant Chemotherapy(NAC) is offered to ER negative, HER2 positive women where tumour size may be reduced. Concerns regarding increased local recurrence rates and length of disease-free survival may influence MDT decision making. Methods This audit reports a single unit experience, over 2 years, in 62 patients who underwent NAC and their radiological and pathological response to treatment. Results: The mean age of this cohort was 46.5 years.Out of 42 symptomatic(67.7%) patients 28(45%) presented within 4 weeks. Eight(12.9%) were screen detected.Commonest TNM presentation was T2(33)N1(35)M0(59). Indication for NAC was breast conservation in the majority(54,62%), followed by ER-ve,Her2 +vity(10,16.1%), locally advanced tumour(15,24.1%), inflammatory(8,12.9%) and triple negative tumours in <50 years(11,17.7%). 32 (52%) women had ER positive,13 (21%) had HER2 positive and 20(32%) had triple negative cancers.Excellent radiological(MRI) response was seen in 17(27.4%) and partial response in 38(61.2%) patients.44 (71%) underwent breast conserving surgery(BCS) while 18(29%) had mastectomy. Fifteen(24.19%) had their decision for mastectomy changed after NAC.Eleven(18%) had a complete pathological response(CpR). All patients had undergone surgery within 8 weeks of final NAC. Four(6.4%)patients were reported to have local recurrence(LR) at the conclusion of the audit period.ConclusionPatients offered NAC in our unit fit the criteria suggested by NICE guidelines. Our rates of CpR(18%Vs.15-36.6%), improved BCS rates post NAC(24.9%Vs.16-25%) and LR rates(6.4%Vs.6%) are acceptable and comparable to the literature.
P098
Topic: Non surgical treatments
Introduction: Neoadjuvant Chemotherapy(NAC) is offered to ER negative, HER2 positive women where tumour size may be reduced. Concerns regarding increased local recurrence rates and length of disease-free survival may influence MDT decision making. Methods This audit reports a single unit experience, over 2 years, in 62 patients who underwent NAC and their radiological and pathological response to treatment. Results: The mean age of this cohort was 46.5 years.Out of 42 symptomatic(67.7%) patients 28(45%) presented within 4 weeks. Eight(12.9%) were screen detected.Commonest TNM presentation was T2(33)N1(35)M0(59). Indication for NAC was breast conservation in the majority(54,62%), followed by ER-ve,Her2 +vity(10,16.1%), locally advanced tumour(15,24.1%), inflammatory(8,12.9%) and triple negative tumours in <50 years(11,17.7%). 32 (52%) women had ER positive,13 (21%) had HER2 positive and 20(32%) had triple negative cancers.Excellent radiological(MRI) response was seen in 17(27.4%) and partial response in 38(61.2%) patients.44 (71%) underwent breast conserving surgery(BCS) while 18(29%) had mastectomy. Fifteen(24.19%) had their decision for mastectomy changed after NAC.Eleven(18%) had a complete pathological response(CpR). All patients had undergone surgery within 8 weeks of final NAC. Four(6.4%)patients were reported to have local recurrence(LR) at the conclusion of the audit period.ConclusionPatients offered NAC in our unit fit the criteria suggested by NICE guidelines. Our rates of CpR(18%Vs.15-36.6%), improved BCS rates post NAC(24.9%Vs.16-25%) and LR rates(6.4%Vs.6%) are acceptable and comparable to the literature.
Topic: Non surgical treatments
Introduction: Neoadjuvant Chemotherapy(NAC) is offered to ER negative, HER2 positive women where tumour size may be reduced. Concerns regarding increased local recurrence rates and length of disease-free survival may influence MDT decision making. Methods This audit reports a single unit experience, over 2 years, in 62 patients who underwent NAC and their radiological and pathological response to treatment. Results: The mean age of this cohort was 46.5 years.Out of 42 symptomatic(67.7%) patients 28(45%) presented within 4 weeks. Eight(12.9%) were screen detected.Commonest TNM presentation was T2(33)N1(35)M0(59). Indication for NAC was breast conservation in the majority(54,62%), followed by ER-ve,Her2 +vity(10,16.1%), locally advanced tumour(15,24.1%), inflammatory(8,12.9%) and triple negative tumours in <50 years(11,17.7%). 32 (52%) women had ER positive,13 (21%) had HER2 positive and 20(32%) had triple negative cancers.Excellent radiological(MRI) response was seen in 17(27.4%) and partial response in 38(61.2%) patients.44 (71%) underwent breast conserving surgery(BCS) while 18(29%) had mastectomy. Fifteen(24.19%) had their decision for mastectomy changed after NAC.Eleven(18%) had a complete pathological response(CpR). All patients had undergone surgery within 8 weeks of final NAC. Four(6.4%)patients were reported to have local recurrence(LR) at the conclusion of the audit period.ConclusionPatients offered NAC in our unit fit the criteria suggested by NICE guidelines. Our rates of CpR(18%Vs.15-36.6%), improved BCS rates post NAC(24.9%Vs.16-25%) and LR rates(6.4%Vs.6%) are acceptable and comparable to the literature.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}